Hepatocellular carcinoma is a common and highly malignant disease. As a currently designated systemic chemotherapeutic agent for advanced Hepatocellular carcinoma. sorafenib has been confronted with dilemma of drug-resistance caused by tumor hypoxia. which hinders the therapeutic efficacy of the drug. https://www.socialstudiesscholar.com/